Marshall Brown, DO
Family Medicine · Pasco, WANPI 1275556904
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $67,700 of the $69,573 with a category attached, or 97.3%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 99.6% of it on its own, with 7 other manufacturers making up the rest. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $1391.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$69K
- AstraZeneca$78
- Bayer$53
- Pfizer$41
- Exact Sciences$22
- Merck$21
- plus $28 from 2 others
What the payments were for
- Consulting fees$67,70097%
- Travel & lodging$1,1532%
- Food & beverage$2440%
- Education$4751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $69,328 |
| AstraZeneca | 4 | $78 |
| Bayer | 3 | $53 |
| Pfizer | 2 | $41 |
| Exact Sciences | 1 | $22 |
| Merck | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $11 |
How this compares
$69,573 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $93,186 |
| XareltoRivaroxaban | 47 | $58,069 |
| OzempicSemaglutide | 47 | $49,852 |
| FarxigaDapagliflozin Propanediol | 18 | $23,259 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $12,963 |
| JanuviaSitagliptin Phosphate | 12 | $10,694 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $9,018 |
| TradjentaLinagliptin | 13 | $7,182 |
| Gabapentin | 230 | $6,132 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $5,311 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $4,295 |
| Atorvastatin Calcium | 427 | $3,548 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,474 |
| Pregabalin | 28 | $2,768 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $2,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $93,18669 claims |
| AstraZenecaFarxiga, Symbicort | $78 | $26,73330 claims |
| MerckJanuvia | $21 | $10,69412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Pasco
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
- Ian BennettSeattle$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.